1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.
2. MSD. Omarigliptin (MARIZEV tablets 12.5 mg, 25 mg): Japanese prescribing information. Tokyo: MSD; 2015.
3. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.
4. Merck. Merck submits new drug application to the Japanese Pharmaceuticals and Medical Devices Agency for omarigliptin, an investigational once-weekly DPP-4 inhibitor for type 2 diabetes [media release]. http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-submits-new-drug-application-japanese-pharmaceuticals- . Accessed 24 Nov 2014.
5. Merck. MARIZEV® (Omarigliptin), Merck’s once-weekly DPP-4 inhibitor for type 2 diabetes, approved in Japan [media release]. http://www.businesswire.com/news/home/20150928005491/en/MARIZEV%C2%AE-Omarigliptin-Merck%E2%80%99s-Once-Weekly-DPP-4-Inhibitor-Type . Accessed 28 Sep 2015.